ClinicalTrials.gg
Not yet recruitingNCT06564506Updated Sep 26, 2025

Electroacupuncture for Preventing Postoperative Delirium in Older Adults Undergoing Total Knee Arthroplasty

An interventional study of Disposable acupuncture needles (0.30 × 75 mm) and Placebo needles (0.30 × 25 mm) in Postoperative Delirium, sponsored by Fujian Provincial Hospital. Not yet recruiting at 1 site in China. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-09-26.

Sponsored by Fujian Provincial Hospital · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,460
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Emergence Delirium with a site in China — 64 open to participants now, 65 under way, 1 of them phase 3. Emergence Delirium · China.

Planned enrollment
6th of 111
1,460 · median 225
Started
2025
with 20 others
No phase
70 of 185
29 open now
Primary completion
2026-08
later than 28 of 64 live
Registered
120th of 185
by date

Among the 185 studies in Emergence Delirium with a site in China, this one is the 6th largest by planned enrollment of the 111 interventional ones that give a count, is one of 21 that started in 2025, is one of 70 with no phase, reaches primary completion later than 28 of the 64 other live ones, and was the 120th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

64 of the 185 studies in Emergence Delirium with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Emergence Delirium with a site in China, or all of them as a file.
02

Study summary

Electroacupuncture may improve cognitive function and altered consciousness, but its effect on postoperative delirium in older arthroplasty patients remains unexplored. This study aims to assess the efficacy of electroacupuncture in preventing postoperative delirium in older adults undergoing total knee arthroplasty.

Read the detailed description

Electroacupuncture combines traditional acupuncture with electrical stimulation at specific body points. Recent clinical studies have shown promising results for acupuncture-related techniques in managing perioperative neurocognitive disorders. However, the efficacy of electroacupuncture in preventing postoperative delirium in elderly patients undergoing total knee arthroplasty remains unexplored.This randomised controlled trial aims to evaluate the efficacy of electroacupuncture in preventing postoperative delirium in elderly patients undergoing total knee arthroplasty.

03

Conditions studied

  • Postoperative Delirium

Browse trials for

Keywords

  • Older adults
  • Electroacupuncture
  • Postoperative delirium
  • Total knee arthroplasty
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 65-90 years
  • American Society of Anaesthesiologists (ASA) physical status class II or III
  • Scheduled for elective unilateral total knee arthroplasty under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • Baseline dementia or (MMSE) score below 24
  • Implanted electrical devices (eg, pacemakers, brain or spinal cord neurostimulator)
  • Infection or abscess at any selected acupuncture point
  • Severe hematopoietic or hemorrhagic disease
  • Severe audio-visual impairments or inability to communicate in Mandarin
  • Alcohol or illicit drug misuse disorder
  • Current use of sedatives, antidepressants or
  • Received acupuncture or electroacupuncture within one month before surgery
  • Any condition deemed unsafe or unsuitable by the research team
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,460 participants (estimated)

Study arms

  • Experimental
    Active electroacupuncture group

    Participants will receive 30 minutes of active electroacupuncture before anaesthesia induction. Experienced acupuncturists will administer electroacupuncture at Shenting (GV24, 0.5 cun \[≈10 mm\] above the anterior hairline midpoint) and bilateral Benshen (GB13, 3 cun \[≈60 mm\] lateral to GV24). After skin preparation and pad placement, patients will close their eyes. Needles will be inserted 20 to 24 mm into the subgaleal layer at a flat angle, then manually manipulated to elicit de qi sensations (eg, fullness, numbness and soreness). Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.

    Device: Disposable acupuncture needles (0.30 × 75 mm) · Device: SDZ-V electroacupuncture devices

  • Sham comparator
    Sham electroacupuncture group

    Participants will receive 30 minutes of sham electroacupuncture before anaesthesia induction.The sham group will use non-acupuncture points: 20 mm above GV24 and 20 mm lateral to GB13. These points, in different dermatomes from true acupoints, minimise location-specific effects. The procedure will match the active group, excluding needle manipulation, de qi sensation and electrical output.

    Device: Placebo needles (0.30 × 25 mm) · Device: SDZ-V electroacupuncture devices

Interventions

  • DeviceDisposable acupuncture needles (0.30 × 75 mm)

    Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.

  • DevicePlacebo needles (0.30 × 25 mm)

    Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Sham electroacupuncture will use blunt-tipped placebo needles without current output, which retract into their handles to simulate skin insertion.

  • DeviceSDZ-V electroacupuncture devices

    Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.

06

What researchers measure

Primary outcomes

  1. The incidence of postoperative delirium within the first three postoperative days

    The incidence of POD within the first three postoperative days will be assessed using the Confusion Assessment Method (CAM). The CAM evaluates four diagnostic features: (1) acute onset or fluctuating course, (2) inattention, (3) disorganised thinking and (4) altered consciousness. Delirium is diagnosed when features 1 and 2 are present, with either 3 or 4. Blinded investigators will assess for POD at least two hours postsurgery and twice daily (09:00-11:00 and 18:00-20:00) for three days.

    Time frame: At least two hours postsurgery and twice daily (09:00-11:00 and 18:00-20:00) for three days

Secondary outcomes

  1. Delirium severity

    Delirium Rating Scale-Revised-98 (DRS-R-98); range 0-39, higher scores indicate greater severity

    Time frame: At least two hours postsurgery and twice daily (09:00-11:00 and 18:00-20:00) for three days

  2. Delirium subtypes

    Richmond Agitation Sedation Scale (RASS); hypoactive (-3 to 0), hyperactive (+1 to +4) or mixed

    Time frame: At least two hours postsurgery and twice daily (09:00-11:00 and 18:00-20:00) for three days

  3. Cognitive function

    Abbreviated Mental Test Score (AMTS) via telephone at 1, 3, 6 and 12 months postoperatively

    Time frame: At 1, 3, 6 and 12 months postoperatively

  4. Anxiety and depression

    Hospital Anxiety and Depression Scale (HADS); 14-item checklist (7 for anxiety, 7 for depression); each item scored 0-3; total score \>8 suggests mild disorder, \>10 moderate disorder

    Time frame: Assessed preoperatively and daily for three days postoperatively

  5. Postoperative pain

    11-point Numerical Rating Scale (0 = no pain, 10 = worst pain imaginable) at rest and movement

    Time frame: Assessed at 1, 3, 6, 12, 24, 36, 48, 60 and 72 hours postsurgery

  6. Postoperative morphine consumption

    Cumulative morphine use and rescue analgesia recorded over 72 hours postsurgery

    Time frame: During 72 hours postsurgery

  7. Recovery quality

    Chinese version of the 15-item Quality of Recovery Questionnaire (QoR-15); range 0-150, higher scores indicate better recovery

    Time frame: Assessed daily for three days postoperatively

  8. Sleep quality

    Richards-Campbell Sleep Questionnaire (RCSQ); higher mean scores indicate better sleep

    Time frame: Assessed preoperatively and daily for three days postoperatively

  9. Adverse events

    Any adverse events during the study will be documented on the electronic medical records

    Time frame: through study completion, an average of 7 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The individual deidentified participant data, the study protocol, and the statistical analysis plan can be accessed from the corresponding author upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: from 3 months after publication, until 5 years.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Aug 2026, 9 months later.

Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 9 months is below that.

Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 21, 2024
StartEst.
Nov 10, 2025
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06564506
Lead sponsor
Fujian Provincial Hospital
Responsible party
Yao Yusheng (Professor, Fujian Provincial Hospital) — Principal investigator
First posted
Aug 21, 2024
Start date
Nov 10, 2025 (estimated)
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Sep 26, 2025

Study contacts

Yusheng Yao, MD
Contact
fjslyys@126.com
+86-13559939629
Yusheng Yao, MD
principal investigator · Fujian Provincial Hospital, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion